The Chinese contract research, development and manufacturing organization (CRDMO) WuXi XDC has launched a bid to raise up to HK$3.7 billion (US$470.3 million) in an initial public offering (IPO) on the Hong Kong Stock Exchange.
Intellegens, a company applying machine learning (ML) to accelerate innovation in R&D, has secured a £1.6m grant from Innovate UK, to apply ML in the emerging field of oligonucleotide therapies.
Veeva has announced the expansion of its business consulting services to help life sciences organizations achieve “greater speed and efficiency” across the product development lifecycle.
US biopharma Insmed has announced progress across its early-stage research programs at the company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More.
iOnctura, a clinical stage biotech company developing breakthrough therapies for cancer, has announced the peer-reviewed publication of translational research on the novel autotaxin (ATX) inhibitor IOA-289.
UCB and Ariceum have announced a strategic research collaboration to identify and develop systemic targeted radiopharmaceuticals for the treatment of solid tumors and immune-related diseases.
Rosalind Franklin University of Medicine and Science opens its incubator, Helix 51, creating wet lab and research space for the Illinois bioscience hub.
Renaissance BioScience enters a partnership with Mitacs to test its yeast-based, RNAi production platform for biocontrol and biotherapeutics applications.
TriLink BioTechnologies, a subsidiary of Maravai, that provides gene therapy services to researchers, has announced it will relocate to expand the company’s operations.
